NCI生化复发前列腺癌工作组:临床试验设计考量
工作组提出「PSMA+BCR」新术语,建议高危BCR定义为PSA倍增时间≤6个月(无论PET结果),并强调未来试验应探索降阶治疗以减少毒性。
要点
- 提出「PSMA+BCR」新术语,指仅PSMA PET可识别的复发前列腺癌。
- 高危BCR建议定义为PSA倍增时间≤6个月,不论PET findings。
- 对照组不强制要求全身治疗或MDT,倡导降阶治疗减少毒性。
核心结论
- NCI BCR工作组认为,未来BCR临床试验应区别于传统影像定义的转移性疾病试验设计。
- 工作组强烈倡导未来试验探索降阶治疗,以尽量减少这一相对惰性疾病状态的毒性。
研究设计与样本
- 会议讨论领域包括命名、基线数据采集标准、影像学考量、高危人群界定、MDT或激素治疗要求、生活质量及潜在研究终点。
主要发现
- 工作组定义了新术语「PSMA+BCR」,指仅PSMA PET可识别的复发前列腺癌,与BCR重叠且区别于传统影像定义的转移性激素敏感性前列腺癌。
- 工作组建议高危BCR定义为PSA倍增时间≤6个月,无论PET结果如何。
- 工作组提供了基线数据采集和影像学要求的建议。
- 工作组认为对照组不强制要求全身治疗或MDT。
- 工作组讨论了该疾病领域的新型终点和生活质量指标。
关键数值与推荐
- 高危BCR:PSA倍增时间≤6个月,无论PET findings。
- 新术语「PSMA+BCR」:仅PSMA PET可识别的复发前列腺癌。
- 对照组:不强制要求全身治疗或MDT。
临床怎么用
- 未来BCR试验设计可参考工作组建议的命名、基线数据采集和影像学要求。
- 高危BCR人群可考虑以PSA倍增时间≤6个月界定,不依赖PET结果。
- 试验设计应探索降阶治疗策略以减少毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Biochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasensitive next-generation imaging. Most phase III trials in PCa have focused on metastatic disease, defined by conventional imaging. Despite the emergence of new imaging, clinical trial principles from metastatic studies will not optimize future BCR trials. METHODS: A Working Group convened at the National Cancer Institute on November 13, 2024 (NCI BCR WG). Key areas of discussion included nomenclature, baseline criteria for data capture, imaging considerations, delineation of high-risk populations to be targeted for trial development, requirements of metastasis-directed therapy (MDT) or hormonal therapy, quality-of-life considerations, and potential study end points. RESULTS: The NCI BCR WG defined the novel term "prostate-specific membrane antigen (PSMA)+BCR" to identify the emerging concept of recurrent PCa identifiable only on PSMA positron emission tomography (PET), overlapping with BCR and distinct from metastatic hormone-sensitive PCa as traditionally defined by conventional imaging. The WG suggested defining high-risk BCR with a prostate-specific antigen doubling time of ≤6 months, regardless of PET findings. The WG provided recommendations for baseline data capture and imaging requirements. Neither systemic therapy nor MDT were considered mandatory for control arms. The WG also discussed novel end points and quality-of-life metrics in this disease space. CONCLUSION: These discussions should inform future clinical BCR trials in this distinct disease space relative to metastatic disease defined by conventional imaging. The NCI BCR WG strongly advocates that future trials explore deintensification of treatment to minimize toxicity in this relatively indolent disease state.
引用
- Einstein DJ, Abel ML, Aragon-Ching JB, et al. National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. J Clin Oncol. 2025. PMID: 41129763. doi:10.1200/JCO-25-01693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。